Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target

[1]  H. Kantarjian,et al.  Analysis of Aurora kinase A expression in CD34+ blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia , 2008, Journal of hematopathology.

[2]  P. Sonneveld,et al.  Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. , 2011, Blood.

[3]  M. Yen,et al.  Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients , 2009, Virchows Archiv.

[4]  Feimeng Zheng,et al.  Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. , 2008, Blood.

[5]  R. Medema,et al.  Shared and separate functions of polo-like kinases and aurora kinases in cancer , 2010, Nature Reviews Cancer.

[6]  Qing Jiang,et al.  Roles of Aurora Kinases in Mitosis and Tumorigenesis , 2007, Molecular Cancer Research.

[7]  David Bebbington,et al.  VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo , 2004, Nature Medicine.

[8]  L. Klein-Hitpass,et al.  The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia , 2011, Leukemia.

[9]  J. Peters,et al.  The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore–microtubule attachment and in maintaining the spindle assembly checkpoint , 2003, The Journal of cell biology.

[10]  John M. Walker,et al.  Myeloid Leukemia , 2020, Methods In Molecular Medicine™.

[11]  M. Westergaard,et al.  A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth , 2008, Molecular Cancer Therapeutics.

[12]  H. Soifer,et al.  Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents , 2009, Nucleic acids research.

[13]  L. Greenberger,et al.  Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection , 2010, Gene Therapy.

[14]  K. Mills,et al.  Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts , 2008, Haematologica.

[15]  H. Kantarjian,et al.  Phase I Study to Assess the Safety and Tolerability of AZD1152 In Combination with Low Dose Cytosine Arabinoside In Patients with Acute Myeloid Leukemia (AML) , 2010 .

[16]  Stephen S. Taylor,et al.  Aurora-kinase inhibitors as anticancer agents , 2004, Nature Reviews Cancer.

[17]  H. Koeffler,et al.  AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. , 2007, Blood.

[18]  R. Poon.  Aurora B , 2013, Cell cycle.

[19]  J. Schellens,et al.  Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Taizo Tasaka,et al.  A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia , 2007, Molecular Cancer Therapeutics.

[21]  J. Fitzgibbon,et al.  AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. , 2009, Cancer research.

[22]  M. Furihata,et al.  Analysis of Aurora B kinase in non-Hodgkin lymphoma , 2009, Laboratory Investigation.

[23]  H. Katayama,et al.  Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. , 1998, Cancer research.

[24]  T. Ikezoe,et al.  p53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells , 2010, International journal of hematology.

[25]  P. Chieffi,et al.  Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation , 2006, The Prostate.

[26]  G. Giaccone,et al.  Frequent overexpression of aurora B kinase, a novel drug target, in non–small cell lung carcinoma patients , 2006, Molecular Cancer Therapeutics.

[27]  E. Rego,et al.  High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia. , 2011, Leukemia research.

[28]  Rajesh Odedra,et al.  AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis , 2007, Clinical Cancer Research.

[29]  C. Pui,et al.  Biology, risk stratification, and therapy of pediatric acute leukemias: an update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Peter J Houghton,et al.  Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP) , 2010, Pediatric blood & cancer.

[31]  J. Berlin,et al.  Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics? , 2010, Molecular Cancer Therapeutics.

[32]  G. Antonoff.  What is a phase , 1944 .

[33]  C. Zwaan,et al.  Pediatric acute myeloid leukemia: towards high-quality cure of all patients , 2007, Haematologica.

[34]  T. Yamauchi,et al.  A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia. , 2011, Leukemia research.

[35]  Stephen S. Taylor,et al.  Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores , 2003, The Journal of cell biology.

[36]  J. Fitzgibbon,et al.  AZD 1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells In vitro and In vivo , 2009 .